Ergothioneine Encyclopedia — Scientific Background

What Is Ergothioneine?

Ergothioneine (EGT), also known as L-ergothioneine or 2-mercaptohistidine trimethylbetaine, is a naturally occurring sulfur-containing amino acid and a potent antioxidant. It is synthesized exclusively by certain bacteria and fungi, particularly mushrooms, and is acquired by humans through dietary intake. EGT is unique among antioxidants in that it is actively accumulated in cells via a specific transporter, OCTN1 (SLC22A4), and is selectively concentrated in tissues under oxidative stress.

The Longevity Vitamin

Ergothioneine has been characterized as a “longevity vitamin” due to its unique physiological role and its association with healthy aging. Unlike conventional antioxidants, EGT is not synthesized endogenously in humans and is acquired exclusively through dietary intake. It is actively accumulated in cells via the OCTN1 transporter, which is broadly expressed in human tissues including the liver, kidneys, eyes, brain, and skin. The unique tissue distribution and active accumulation of EGT in metabolically active and stress-prone tissues underscore its role as a cellular protectant.

Dietary Sources

Ergothioneine is found in various food sources, with mushrooms being the primary dietary source:

• Mushrooms — Shiitake (Lentinula edodes) contains the highest ergothioneine content among evaluated mushroom species; golden oyster (Pleurotus citrinopileatus), king oyster (P. eryngii), and maitake (Grifola frondosa) are also notable sources

• Other food sources — Smaller amounts are found in liver, beans, oats, algae, and tempeh

It is estimated that approximately 95% of ergothioneine in the human diet comes from mushrooms.

Mechanisms of Action

Mitochondrial Protection

Ergothioneine actively accumulates in mitochondria, where it exerts its primary antioxidant effects. In oxidative stress-challenged human dermal fibroblasts, EGT preserves mitochondrial integrity by maintaining mitochondrial signal and morphology, restoring membrane potential, and suppressing mitochondrial superoxide accumulation. This mitochondrial-targeting capacity distinguishes EGT from many conventional antioxidants and underscores its role in cellular energy homeostasis.

OCTN1 Transporter-Mediated Uptake

The organic cation transporter OCTN1 (SLC22A4) is the primary transporter responsible for intestinal uptake, tissue distribution, and renal retention of EGT. OCTN1 is widely expressed in various organs and cells and is responsible for the unique tissue distribution of EGT. EGT is not synthesized endogenously in mammals but is acquired from the diet via this transporter. EGT has been shown to provoke its transporter OCTN1 expression, suggesting a positive feedback mechanism for enhanced uptake.

Antioxidant Defense

Ergothioneine is a powerful antioxidant with free radical scavenging ability comparable to ascorbic acid. It scavenges free radicals and protects cells from UV-induced ROS with higher efficiency than antioxidants Coenzyme Q10 or idebenone. The thione tautomeric form of EGT confers remarkable structural stability, enabling it to function as a stable antioxidant in biological systems.

Anti-Inflammatory and Cytoprotective Effects

EGT exhibits anti-inflammatory and cytoprotective properties. It modulates inflammatory responses and protects cells from oxidative damage. Experimental studies have demonstrated antioxidant, cytoprotective, and anti-inflammatory properties of ergothioneine, suggesting its potential role in supporting healthy aging.

Neuroprotective Effects

Ergothioneine has demonstrated neuroprotective properties, including stimulation of Ca²⁺-mediated Brain-Derived Neurotrophic Factor (BDNF) expression in nerve cells and promotion of neuronal differentiation through activation of mTORC1 and NT5/TrkB signaling in neural stem cells.

Stability Profile

Ergothioneine exhibits exceptional stability compared to many antioxidants. Studies have demonstrated that EGT has excellent light, thermal, and acid-base stability. It is a stable antioxidant molecule that does not degrade at high temperature and high pH. However, the presence of Cu²⁺ decreases the concentration of EGT. This stability profile makes EGT suitable for a wide range of formulation applications, including functional beverages and food products.

Clinical Evidence

Sleep Quality

A randomized, double-blind, placebo-controlled study evaluated the effects of 8 mg/day EGT or placebo for 16 weeks. Subjective sleep quality was significantly improved in the EGT group compared to the placebo group (p < 0.05). A PBPK modeling study further estimated that 8 mg/day of EGT for 16 weeks is optimal for attaining an effective plasma EGT concentration.

Skin Health

An 8-week, randomized, double-blind, placebo-controlled trial in 66 women aged 35–59 years evaluated the effects of continuous oral intake of 30 mg/day EGT or placebo. The study demonstrated that EGT significantly improved skin aging parameters, with wrinkle and spot reduction observed (all p < 0.01). No adverse events were reported, confirming excellent safety and tolerability.

Postpartum Recovery

A randomized, double-blind, placebo-controlled trial evaluated the efficacy of EGT supplementation (120 mg/day) on postpartum fatigue, sleep quality, and quality of life. The study concluded that EGT supplementation safely accelerates postpartum functional recovery, offering rapid relief from mental fatigue and sleep disturbances within 15 days.

Ovarian Reserve and Reproductive Aging

A single-center, open-label, self-controlled pilot study enrolled 40 women aged 35–45 years with suboptimal ovarian reserve. Participants received oral EGT (120 mg/day) for three consecutive menstrual cycles. EGT supplementation was associated with increases in serum AMH (mean change +0.65 ng/mL, 95% CI [0.14, 1.17], p = 0.018), decreased basal FSH (mean change −1.33 mIU/mL, 95% CI [−2.50, −0.17], p = 0.032), and increased E2 (mean change +19.69 pg/mL, 95% CI [3.99, 35.38], p = 0.019). Clinical assessments showed progressive reductions in KI scores (5.42 ± 3.66 to 1.90 ± 2.16, p < 0.0001) and PSQI scores (6.89 ± 1.82 to 5.50 ± 1.40, p < 0.0001), alongside improved menstrual and SF-36 scores (p < 0.001).

Safety and Regulatory

Ergothioneine possesses a favorable safety profile. Current toxicological and clinical evidence indicates that EGT is well tolerated due to its structural stability, transporter-regulated uptake, and metabolic inertness. Subchronic toxicity studies have established a no-observed-adverse-effect level (NOAEL) of 800 mg/kg body weight, with no observed adverse effects at the highest doses tested. Genotoxicity and reproductive developmental toxicity tests have been negative. Clinical trials using EGT at doses up to 120 mg/day have reported no product-related adverse events. In the European Union, L-ergothioneine has been authorized as a novel food ingredient. Testing protocols must adhere to international standards including USP, European Pharmacopoeia, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.

This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.

659$/KG

459$/KG